Histoplasmosis in immunosuppressed patients

Area of Science:

• Mycology
• Infectious Diseases
• Immunology

Background:

• Histoplasma capsulatum infection poses a significant risk to individuals with compromised immune systems.
• Hematologic malignancies like Hodgkin's disease and leukemia are common underlying conditions in patients with disseminated histoplasmosis.
• Treatment with cytotoxic drugs and corticosteroids further increases susceptibility to opportunistic infections.

Purpose of the Study:

• To analyze the clinical characteristics, diagnosis, and treatment outcomes of Histoplasma capsulatum infection in immunosuppressed patients.
• To identify the most effective diagnostic methods and therapeutic strategies for managing histoplasmosis in this vulnerable population.

Main Methods:

• Retrospective analysis of 58 immunosuppressed patients (16 new, 42 previous cases) with Histoplasma capsulatum infection.
• Review of underlying diseases, treatments received, clinical presentation, diagnostic procedures, and therapeutic responses.
• Evaluation of diagnostic utility of bone marrow biopsy, tissue biopsies (oral lesions, lung, liver, lymph node), fungal culture, and serologic methods.
• Assessment of treatment outcomes based on amphotericin B dosage and timing of diagnosis.

Main Results:

• 88% of patients presented with widely disseminated infection, primarily affecting the lungs and reticuloendothelial system.
• Bone marrow biopsy with microscopic examination for yeast forms was the most reliable diagnostic method.
• Fungal culture and serologic tests showed limited diagnostic value in acutely ill patients.
• Early diagnosis and a full course of amphotericin B therapy resulted in a low mortality rate (6.7%).
• Patients receiving no or limited amphotericin B had a 100% mortality rate.

Conclusions:

• Histoplasmosis is a severe, often disseminated infection in immunosuppressed patients, frequently associated with hematologic malignancies.
• Prompt diagnosis, particularly through bone marrow biopsy, is crucial for effective management.
• Aggressive treatment with amphotericin B, initiated early, dramatically improves survival outcomes, while inadequate treatment leads to high mortality.